The sphingosine-1-phosphate receptor : A novel therapeutic target for multiple sclerosis and other autoimmune diseases
Copyright © 2016 Elsevier Inc. All rights reserved.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 175(2017) vom: 15. Feb., Seite 10-15 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2017
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Lysophospholipids Receptors, Lysosphingolipid sphingosine 1-phosphate 26993-30-6 Sphingosine NGZ37HRE42 |
| Zusammenfassung: | Copyright © 2016 Elsevier Inc. All rights reserved. Multiple sclerosis (MS) is a prototype autoimmune disease of the central nervous system (CNS). Currently, there is no drug that provides a cure for MS. To date, all immunotherapeutic drugs target relapsing remitting MS (RR-MS); it remains a daunting medical challenge in MS to develop therapy for secondary progressive MS (SP-MS). Since the approval of the non-selective sphingosine-1-phosphate (S1P) receptor modulator FTY720 (fingolimod [Gilenya®]) for RR-MS in 2010, there have been many emerging studies with various selective S1P receptor modulators in other autoimmune conditions. In this article, we will review how S1P receptor may be a promising therapeutic target for SP-MS and other autoimmune diseases such as psoriasis, polymyositis and lupus |
|---|---|
| Beschreibung: | Date Completed 05.06.2017 Date Revised 22.08.2019 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2016.11.008 |